The University of Chicago Header Logo

Connection

Ravi Salgia to Heterocyclic Compounds, 3-Ring

Back to Details
This is a "connection" page, showing publications Ravi Salgia has written about Heterocyclic Compounds, 3-Ring.
Ravi Salgia
Connection Strength
0.033
Heterocyclic Compounds, 3-Ring
  1. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.